Recent reports showed that anti-PD-1/anti-PD-L1-based combination therapy represented a promising strategy for HCC (64), and targeting TBK1 boosted the efficacy of anti-PD-1/anti-PD-L1 in various types of cancer (16, 18). The gene discussed is PDCD1; the disease is cancer.